Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nurix Therapeutics, Inc. (Nasdaq: NRIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on targeted protein degradation medicines, Nurix uses its 10-K, 10-Q and 8-K reports to describe pipeline progress, financing activities, collaborations and governance matters.
Recent Form 8-K filings illustrate the types of information NRIX investors can monitor here. One 8-K details an underwriting agreement for a registered offering of common stock under a shelf registration statement, including intended uses of proceeds such as funding clinical development of the BTK degrader bexobrutideg in chronic lymphocytic leukemia, exploring autoimmune indications, expanding the research pipeline and supporting general corporate purposes. Other 8-Ks report on the initiation of the pivotal DAYBreak Phase 2 study of bexobrutideg in relapsed or refractory CLL/SLL, updated clinical data for NX-1607, and changes to the board of directors and committee roles.
Through this page, users can review current and historical SEC documents related to Nurix’s common stock listed on the Nasdaq Global Market under the symbol NRIX. Filings may cover topics such as results of operations, equity offerings, clinical development milestones, collaboration agreements with partners like Gilead, Sanofi and Pfizer, and appointments or resignations of directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand material events without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K and other forms appear promptly, while dedicated sections make it easier to locate items related to capital raises, clinical trial disclosures or governance changes. For those tracking insider activity, Form 4 and related ownership filings can also be accessed to see how Nurix’s insiders transact in NRIX shares.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 5,394 shares of common stock on May 1, 2026 at a weighted average price of $16.7606 per share. The sale was executed under a previously adopted Rule 10b5-1 trading plan, with individual sale prices ranging from $16.26 to $16.97. Following this transaction, she directly holds 26,453 shares of Nurix common stock.
The filing is a Form 144 notice reporting proposed sales of Common Stock tied to Restricted Stock Units. The document lists 5,394 RSUs with an effective/record date of 04/30/2026 and multiple planned or effected 10b5-1 sales by Christine Ring on dates in 02/09/2026, 03/02/2026, 04/02/2026, and 04/30/2026.
Nurix Therapeutics Chief Financial Officer Hans van Houte reported routine equity compensation activity tied to restricted stock units (RSUs). On April 30, 2026, RSUs covering 8,608 shares of common stock vested and were converted into common shares.
To satisfy associated tax withholding obligations, 2,388 common shares were sold in an open-market transaction at a weighted average price of $16.6453 per share. The company’s equity plan required this "sell to cover" transaction, and the filing states it did not represent a discretionary trade by the executive.
Following these transactions, Hans van Houte directly holds 51,647 shares of Nurix common stock. The RSU awards vest in quarterly installments over three years, with separate grants beginning to vest on July 30, 2023, July 30, 2024, and July 30, 2025, contingent on continued service. Each RSU represents a right to receive one share of common stock upon vesting.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring had restricted stock units vest and related share movements on April 30, 2026. She sold 3,214 shares of common stock at a weighted average of $16.6453 per share solely to cover tax withholding on the RSU vesting, under the company’s mandatory “sell to cover” policy, so the sale was not a discretionary trade. In connection with the vesting, she acquired a total of 8,608 shares of common stock through RSU conversions.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported compensation-related stock activity involving vested restricted stock units and a small mandated share sale. On April 30, 2026, she exercised RSUs into a total of 8,608 shares of common stock.
On the same date, she sold 3,214 shares of common stock at a weighted average price of $16.6453 per share solely to cover tax withholding obligations under Nurix’s equity incentive plans. These “sell to cover” transactions were not discretionary trades. After these transactions, she held 120,399 common shares directly.
Redmile Group, LLC reports beneficial ownership of 10,696,314 shares of Nurix Therapeutics common stock, representing 9.9% of the class. The count includes 3,664,406 shares issuable upon exercise of certain pre-funded warrants subject to a Beneficial Ownership Limitation of 9.99%. RedCo II Offshore SPV LLC is reported with 5,967,424 shares (5.6%) following an internal reorganization that moved holdings from RedCo II Master Fund, L.P., which now reports 0 shares. Shares outstanding were 103,405,813 as of April 1, 2026 per the company Form 10-Q; warrant issuable amounts are presented separately and are factored into the percentage calculations per the filing.
Nurix Therapeutics, Inc. reported higher losses for the quarter ended February 28, 2026 as it invested heavily in its targeted protein degradation pipeline. Collaboration revenue fell to $6.3 million from $18.5 million a year earlier, mainly reflecting timing of milestone and research activities.
Research and development expenses rose to $84.1 million from $69.7 million, driving a net loss of $87.2 million versus $56.4 million in the prior-year quarter. Operating cash outflow was $71.9 million, while cash, cash equivalents and marketable securities totaled $540.7 million, which management believes is sufficient for at least 12 months of operations.
The company continues to advance clinical programs including BTK degraders bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127), and CBL‑B inhibitor NX‑1607. It maintains sizable collaboration potential with Gilead, Sanofi and Pfizer and access to equity financing through at-the-market and registered direct offerings.
Nurix Therapeutics reported fiscal first quarter 2026 results and updated progress across its clinical pipeline. Revenue was $6.3 million, down from $18.5 million a year earlier as certain Sanofi collaboration research terms ended. Research and development expenses rose to $84.1 million and general and administrative costs increased to $14.6 million, reflecting expanded clinical activity.
Net loss widened to $87.2 million, or ($0.79) per share, compared with ($0.67) per share in the prior-year quarter. Nurix ended the quarter with $540.7 million in cash, cash equivalents and marketable securities. The company highlighted ongoing Phase 2 and planned Phase 3 studies of bexobrutideg in relapsed/refractory chronic lymphocytic leukemia, additional oncology programs, and partnered degraders with Gilead and Sanofi.
Nurix Therapeutics Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction. The weighted average sale price was $15.2367 per share, with individual trades ranging from $15.00 to $15.43. Following the sale, she directly holds 26,453 Nurix shares. The transaction was executed under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary trade.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Rule 144 notice listing 8,148 shares of Common stock tied to Restricted Stock Units dated 05/02/2022 for resale. The filing also lists recent 10b5-1 sales by Christine Ring on 03/02/2026, 02/09/2026 and 01/20/2026 showing multiple executed transactions and dollar amounts.